Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Astrazeneca AB, et al v. Apotex Corporation, et al
Case Number:
1:01-cv-09351
Court:
Nature of Suit:
Judge:
Firms
- Amster Rothstein
- Caesar Rivise
- Husch Blackwell
- Jones Day
- Katten Muchin
- Law Offices of Karen J. Bernstein
- Milbank LLP
- Paul Weiss
- Pryor Cashman
- Robinson & Cole
- Robinson Curley
- Sidley Austin
- Winston & Strawn
Companies
Sectors & Industries:
-
June 30, 2015
Apotex To Pay AstraZeneca $98M For Prilosec IP Infringement
A New York federal judge on Tuesday ordered Apotex Corp. to pay $98.5 million to AstraZeneca AB for infringing two patents covering the latter's indigestion drug Prilosec, about three months after the Federal Circuit left intact most of a $76 million damages award.
-
December 03, 2013
AstraZeneca Deserves $76M In Drug Patent Suit, Judge Says
AstraZeneca AB has successfully demonstrated that it is entitled to more than $76 million for Canada-based Apotex Corp. and Torpharm Inc.'s infringement of patents that protected the company's indigestion drug Prilosec, according to a New York federal judge's ruling unsealed Tuesday.